

Advances and Insights into Neurological Practice 2016-17

AHV Schapira

Papers published by the European Journal of Neurology reflect the broad interest of practicing neurologists in advances in the aetiology, diagnosis and management of neurological disorders. As a general neurology journal, the proportion of papers in the different subject areas reasonably reflects the case load of a practising neurologist.

Stroke represents the largest proportion of papers published, including those on pathophysiology (1-23), acute stroke management (24-47) and the outcome of patients who have suffered stroke (48-72). Stroke is a world-wide problem, but its prevalence varies and may reflect both the genetic and environmental contributions to stroke, both in turn reflecting the known risk factors for stroke. It is of note that vascular risk factors were less prevalent in the Middle East compared to the USA, with the exception of diabetes and smoking (3). Thus targeting this Middle East population with education and lifestyle changes would appear to be particularly relevant. The potential genetic contribution to stroke was highlighted by a study from Sweden of young onset strokes (age < 55 years), 47% had a family history (5). An interesting finding from Korea reported that sleep duration > 8 hours was significantly associated with an increased risk for intracerebral haemorrhage that was dose dependent: 8h OR 1.57, > 9h OR 5.0 (11). The incidence of intracerebral haemorrhage appears to be declining (19), perhaps due to better management of hypertension and other risk factors. Of concern is that there is under anti-coagulation treatment of atrial fibrillation, a recognised risk factor for stroke (45).

The advances in our understanding of the cause, progress, management and treatments available for multiple sclerosis have transformed the outlook for many patients with this disorder (73-104). Recent information on risk factors includes the recognition that low vitamin D increases risk, and that vitamin D may provide a neuroprotective effect (86, 89). An epidemiological study from Canada found a protective effect of low socio-economic status from developing MS, although this was not found in other countries (88).

Parkinson disease (PD) in its early years can be well managed with symptomatic dopaminergic therapy (105-125), while other movement disorders are less satisfactorily treated (126-134). The development of motor complications is a significant limitation to the long term use of levodopa. A community based incident cohort in Scotland found that 21.3% developed motor fluctuations and 28.4% dyskinesias after 59 months (108). Cumulative levodopa dose, age at diagnosis and female sex were identified as associated with motor complications, confirming previous studies in this area. As PD progresses, parenteral therapy may be required, and this includes the use of intestinal levodopa infusions to help control motor function and improve dyskinesias. Of a longitudinal study of 33 levodopa infusion patients, at baseline, 3 had developed peripheral neuropathy and 7 had subclinical neuropathy (111). At 2 years following levodopa infusion, four patients with normal neurophysiology at baseline developed subclinical neuropathy, and a

further seven developed a subclinical neuropathy. Peripheral neuropathy in PD is said to have a prevalence of 55% compared to 9% in age-matched controls (110). Alpha-synuclein pathology in the peripheral nerves may contribute, as may levodopa related metabolic disturbances such as low vitamin B12 and B6, and increased methylmalonic acid and homocysteine. The association with levodopa is cumulative dose related.

A significant advance in our understanding of the pathogenesis of PD has come from the observation that mutations of the glucocerebrosidase (GBA) gene are numerically the most important risk factor for development of the disease. Furthermore, PD patients without GBA mutations exhibit low GBA enzyme activity resulting from accumulation of alpha-synuclein. GBA mutations are also strongly associated with the risk for dementia with Lewy bodies, highlighting the link between GBA and the synucleinopathies. However, the prevalence of GBA mutations in multiple system atrophy has not been consistently found to be increased and a recent study from Germany found no increase in progressive supranuclear palsy, primary progressive aphasia or frontotemporal dementia, two of 39 patients with corticobasal syndrome had mutations (116). Another genetic study in PD, focussing on the mitochondrial genome found associations between haplotypes and both increased and reduced risk for PD (117). These findings were supported by functional analyses using cybrids.

The neurodegenerative diseases constitute major economic and social as well as medical challenges (135-162). The association of dementia with income, mortality, morbidity and medication use has been highlighted with a study from Denmark (155), with effects seen years before diagnosis. The additional healthcare costs and lost productivity prior to diagnosis was estimated at 2082 euros per patient more than matched controls. This figure increased to 4544 euros per patient after diagnosis. In the UK, the average annual cost of caring for a patient with Huntington's disease is 24,000 euros, 16,000 euros of which was informal care for inside and outside the home (161). These figures highlight the considerable potential for investing in research to slow, stop or prevent these and other neurodegenerative diseases. Advances in our knowledge on the genetics and environmental associations in amyotrophic lateral sclerosis promise to provide important insights into potential strategies to reduce risk and highlight potential treatments (163-176).

Epilepsy likewise represents another neurological disorder with significant societal and economic consequences, as well as medical (177-190). Treatments for epilepsy have been available for many years; a recent study on the long term prognosis of epilepsy found 59% of patients were seizure free, with a progressive increase in remission over time (184). Thus the long term prognosis of epilepsy is favourable, but poor prognosis for remission can be predicted with reasonable accuracy.

Neuromuscular disorders (191-213), trauma (214-215), neuro-inflammation (216-223), headache (224-231) and more general neurological topics (232-248) complete the 2016 spectrum of the Journal's purview.

References

Stroke – Pathophysiology

1. Damania D, Kung NT, Jain M, Jain AR, Liew JA, Mangla R, Koch GE, Sahin B, Miranpuri AS, Holmquist TM, Replogle RE, Benesch CG, Kelly AG, Jahromi BS. Factors associated with recurrent stroke and recanalization in patients presenting with isolated symptomatic carotid occlusion. *Eur J Neurol* 2016; 23: 127-32.
2. Miller DJ. Increasing the yield of atrial fibrillation detection in cryptogenic stroke using risk factor stratification: a more satisfying approach. *Eur J Neurol* 2016; 23: 239-40.
3. Behrouz R, Powers CJ. Epidemiology of classical risk factors in stroke patients in the Middle East. *Eur J Neurol* 2016; 23: 262-9.
4. Poli S, Diedler J, Hartig F, Gotz N, Bauer A, Sachse T, Muller K, Muller I, Stimpfle F, Duckheim M, Steeg M, Eick C, Schrieck J, Gawaz M, Ziemann U, Zuern CS. Insertable cardiac monitors after cryptogenic stroke--a risk factor based approach to enhance the detection rate for paroxysmal atrial fibrillation. *Eur J Neurol* 2016; 23: 375-81.
5. Ilinca A, Kristoffersson U, Soller M, Lindgren AG. Familial aggregation of stroke amongst young patients in Lund Stroke Register. *Eur J Neurol* 2016; 23: 401-7.
6. Katsanos AH, Giannopoulos S, Frogoudaki A, Vrettou AR, Ikonomidis I, Paraskevaidis I, Zompola C, Vadikolias K, Boviatsis E, Parissis J, Voumvourakis K, Kyritsis AP, Tsivgoulis G. The diagnostic yield of transesophageal echocardiography in patients with cryptogenic cerebral ischaemia: a meta-analysis. *Eur J Neurol* 2016; 23: 569-79.
7. Kim Y, Kim TJ, Park JB, Lee S, Kim YJ, Lee JS, Lee SH. Novel echocardiographic indicator for potential cardioembolic stroke. *Eur J Neurol* 2016; 23: 613-20.
8. Xie S, Lu L, Liu L, Bi G, Zheng L. Progranulin and short-term outcome in patients with acute ischaemic stroke. *Eur J Neurol* 2016; 23: 648-55.
9. Qiu J, Zhou Y, Yang X, Zhang Y, Li Z, Yan N, Wang Y, Ge S, Wu S, Zhao X, Wang W. The association between ankle-brachial index and asymptomatic cranial-carotid stenosis: a population-based, cross-sectional study of 5440 Han Chinese. *Eur J Neurol* 2016; 23: 757-62.
10. Camilo MR, Pontes-Neto OM. Is long sleep duration a risk factor for intracerebral hemorrhage? *Eur J Neurol* 2016; 23: 989-90.
11. Kim TJ, Kim CK, Kim Y, Jung S, Jeong HG, An SJ, Ko SB, Yoon BW. Prolonged sleep increases the risk of intracerebral haemorrhage: a nationwide case-control study. *Eur J Neurol* 2016; 23: 1036-43.
12. Siniscalchi A. DWI-MRI and Fabry disease: what can we learn? *Eur J Neurol* 2016; 23: 1143-4.
13. Jimenez MC, Curhan GC, Choi HK, Forman JP, Rexrode KM. Plasma uric acid concentrations and risk of ischaemic stroke in women. *Eur J Neurol* 2016; 23: 1158-64.
14. Tanislav C, Grittner U, Fazekas F, Thijs V, Tatlisumak T, Huber R, von SB, Putaala J, Schmidt R, Kropp P, Norrving B, Martus P, Gramsch C, Giese AK, Rolfs A, Enzinger C. Frequency and predictors of acute ischaemic lesions on brain magnetic resonance imaging in young patients with a clinical diagnosis of transient ischaemic attack. *Eur J Neurol* 2016; 23: 1174-82.

15. Kellert L, Kloss M, Pezzini A, Debette S, Leys D, Caso V, Thijs VN, Bersano A, Touze E, Tatlisumak T, Traenka C, Lyrer PA, Engelter ST, Metso TM, Grond-Ginsbach C. Prognostic significance of pulsatile tinnitus in cervical artery dissection. *Eur J Neurol* 2016; 23: 1183-7.
16. Jashari F, Ibrahim P, Bajraktari G, Gronlund C, Wester P, Henein MY. Carotid plaque echogenicity predicts cerebrovascular symptoms: a systematic review and meta-analysis. *Eur J Neurol* 2016; 23: 1241-7.
17. Norton J, Portet F, Gabelle A, Debette S, Ritchie K, Touchon J, Berr C. Are migraine and non-migrainous headache risk factors for stroke in the elderly? Findings from a 12-year cohort follow-up. *Eur J Neurol* 2016; 23: 1463-70.
18. Leira Y, Lopez-Dequidt I, Arias S, Rodriguez-Yanez M, Leira R, Sobrino T, Campos F, Blanco M, Blanco J, Castillo J. Chronic periodontitis is associated with lacunar infarct: a case-control study. *Eur J Neurol* 2016; 23: 1572-9.
19. Sacco S, Ornello R, Degan D, Tiseo C, Pistoia F, Carolei A. Declining incidence of intracerebral hemorrhage over two decades in a population-based study. *Eur J Neurol* 2016; 23: 1627-34.
20. Bohm M. Heart rate as emerging risk indicator in stroke - the beat goes on. *Eur J Neurol* 2016; 23: 1698-9.
21. Soderholm M, Almgren P, Jood K, Stanne TM, Olsson M, Ilinca A, Lorentzen E, Norrving B, Engstrom G, Melander O, Jern C, Lindgren A. Exome array analysis of ischaemic stroke: results from a southern Swedish study. *Eur J Neurol* 2016; 23: 1722-8.
22. Nolte CH, Erdur H, Grittner U, Schneider A, Piper SK, Scheitz JF, Wellwood I, Bath PM, Diener HC, Lees KR, Endres M. Impact of heart rate on admission on mortality and morbidity in acute ischaemic stroke patients - results from VISTA. *Eur J Neurol* 2016; 23: 1750-6.
23. Xu T, Zhong C, Peng Y, Chen CS, Wang J, Ju Z, Li Q, Geng D, Sun Y, Zhang D, Zhang Y, Chen J, Xu T, Zhang Y, He J. Serum 25-hydroxyvitamin D deficiency predicts poor outcome amongst acute ischaemic stroke patients with low high density lipoprotein cholesterol. *Eur J Neurol* 2016; 23: 1763-8.

Stroke - Acute

24. Reuter B, Gumbinger C, Sauer T, Wietholter H, Bruder I, Rode S, Ringleb PA, Kern R, Hacke W, Hennerici MG. Intravenous thrombolysis for acute ischaemic stroke in the elderly: data from the Baden-Wuerttemberg stroke registry. *Eur J Neurol* 2016; 23: 13-20.
25. Seet RC. Ischaemic stroke patients who present early but with therapeutic anticoagulation: a treatment dilemma. *Eur J Neurol* 2016; 23: 227-8.
26. Yan B. Strategies to enable equitable delivery of acute endovascular treatment to stroke patients. *Eur J Neurol* 2016; 23: 229-30.
27. Rozeman AD, Wermer MJ, Nijeholt GJ, Dippel DW, Schonewille WJ, Boiten J, Algra A. Safety of intra-arterial treatment in acute ischaemic stroke patients on oral anticoagulants. A cohort study and systematic review. *Eur J Neurol* 2016; 23: 290-6.
28. Alonso de LM, Fuentes B, Ximenez-Carrillo A, Vivancos J, Masjuan J, Gil-Nunez A, Martinez-Sanchez P, Zapata-Wainberg G, Cruz-Culebras A, Garcia-Pastor A, Diaz-Otero F, Fandino E, Frutos R, Caniego JL, Mendez JC, Fernandez-Prieto A, Barcena-Ruiz E, Diez-Tejedor E. A

- collaborative system for endovascular treatment of acute ischaemic stroke: the Madrid Stroke Network experience. *Eur J Neurol* 2016; 23: 297-303.
29. Liebeskind DS. Hydration and collateral flow in acute stroke. *Eur J Neurol* 2016; 23: 433-4.
 30. Chang SW, Huang YC, Lin LC, Yang JT, Weng HH, Tsai YH, Lee TH. Effect of dehydration on the development of collaterals in acute middle cerebral artery occlusion. *Eur J Neurol* 2016; 23: 494-500.
 31. Tan G, Lei C, Hao Z, Chen Y, Yuan R, Liu M. Liver function may play an uneven role in haemorrhagic transformation for stroke subtypes after acute ischaemic stroke. *Eur J Neurol* 2016; 23: 597-604.
 32. Guettier S, Cogez J, Bonnet AL, Dean P, Apoil M, Tchoumi T, Dubuc L, Arzur J, de IS, V, Kouassi LK, Viader F, Touze E. Factors associated with timing of early neurological improvement after thrombolysis for ischaemic stroke. *Eur J Neurol* 2016; 23: 664-7.
 33. Yan S, Chen Q, Zhang X, Xu M, Han Q, Shao A, Liebeskind DS, Lou M. Extensive blooming artifact predicts no recanalization after intravenous thrombolysis. *Eur J Neurol* 2016; 23: 737-43.
 34. Nikoubashman O, Jungbluth M, Schurmann K, Muller M, Falkenburger B, Tauber SC, Wiesmann M, Schulz JB, Reich A. Neurothrombectomy in acute ischaemic stroke: a prospective single-centre study and comparison with randomized controlled trials. *Eur J Neurol* 2016; 23: 807-16.
 35. Graff-Radford J, Fugate JE, Klaas J, Flemming KD, Brown RD, Rabinstein AA. Distinguishing clinical and radiological features of non-traumatic convexal subarachnoid hemorrhage. *Eur J Neurol* 2016; 23: 839-46.
 36. Serles W, Gattringer T, Mutzenbach S, Seyfang L, Trenkler J, Killer-Oberpfalzer M, Deutschmann H, Niederkorn K, Wolf F, Gruber A, Hausegger K, Weber J, Thurnher S, Gizewski E, Willeit J, Karaic R, Fertl E, Nasel C, Brainin M, Erian J, Oberndorfer S, Karnel F, Grisold W, Auff E, Fazekas F, Haring HP, Lang W. Endovascular stroke therapy in Austria: a nationwide 1-year experience. *Eur J Neurol* 2016; 23: 906-11.
 37. Hu L, Dong MX, Zhao H, Xu GH, Qin XY. Fibulin-5: a novel biomarker for evaluating severity and predicting prognosis in patients with acute intracerebral haemorrhage. *Eur J Neurol* 2016; 23: 1195-201.
 38. Guillan M, DeFelipe-Mimbrera A, Alonso-Canovas A, Matute MC, Vera R, Cruz-Culebras A, Garcia-Barragan N, Masjuan J. The syndrome of transient headache and neurological deficits with cerebrospinal fluid lymphocytosis mimicking an acute stroke. *Eur J Neurol* 2016; 23: 1235-40.
 39. Ajili N, Decroix JP, Preda C, Labreuche J, Lopez D, Bejot Y, Michel P, Sevin-Allouet M, Sibon I, Vergnet S, Wang A, Sanda N, Mazighi M, Bourdain F, Lapergue B. Impact of thrombolysis in acute ischaemic stroke without occlusion: an observational comparative study. *Eur J Neurol* 2016; 23: 1380-6.
 40. Legris N, Hervieu-Begue M, Daubail B, Daumas A, Delpont B, Osseby GV, Rouaud O, Giroud M, Bejot Y. Telemedicine for the acute management of stroke in Burgundy, France: an evaluation of effectiveness and safety. *Eur J Neurol* 2016; 23: 1433-40.
 41. Gill D. Cerebral collateral circulation and acute ischaemic stroke. *Eur J Neurol* 2016; 23: 1696-7.

42. Curtze S, Sibolt G, Melkas S, Mustanoja S, Haapaniemi E, Putaala J, Sairanen T, Tiainen M, Tatlisumak T, Strbian D. Symptomatic post-thrombolytic intracerebral hemorrhage is not related to the cause of stroke. *Eur J Neurol* 2016; 23: 1700-4.
43. Leng X, Lan L, Liu L, Leung TW, Wong KS. Good collateral circulation predicts favorable outcomes in intravenous thrombolysis: a systematic review and meta-analysis. *Eur J Neurol* 2016; 23: 1738-49.
44. Waltimo T, Haapaniemi E, Surakka IL, Melkas S, Sairanen T, Sibolt G, Tatlisumak T, Strbian D. Post-thrombolytic blood pressure and symptomatic intracerebral hemorrhage. *Eur J Neurol* 2016; 23: 1757-62.
45. Palomaki A, Mustonen P, Hartikainen JE, Nuotio I, Kiviniemi T, Ylitalo A, Hartikainen P, Airaksinen KE. Underuse of anticoagulation in stroke patients with atrial fibrillation--the FibStroke Study. *Eur J Neurol* 2016; 23: 133-9.
46. Klaas JP. Two drugs are better than one ... for a while. Duration of dual-antiplatelet therapy following stroke or transient ischaemic attack. *Eur J Neurol* 2016; 23: 991-2.
47. Ge F, Lin H, Liu Y, Li M, Guo R, Ruan Z, Chang T. Dual antiplatelet therapy after stroke or transient ischaemic attack - how long to treat? The duration of aspirin plus clopidogrel in stroke or transient ischaemic attack: a systematic review and meta-analysis. *Eur J Neurol* 2016; 23: 1051-7.

Stroke-Outcomes

48. Kim EJ, Park CH, Chang WH, Lee A, Kim ST, Shin YI, Kim YH. The brain-derived neurotrophic factor Val66Met polymorphism and degeneration of the corticospinal tract after stroke: a diffusion tensor imaging study. *Eur J Neurol* 2016; 23: 76-84.
49. Gronholm EO, Roll MC, Horne MA, Sundgren PC, Lindgren AG. Predominance of caudate nucleus lesions in acute ischaemic stroke patients with impairment in language and speech. *Eur J Neurol* 2016; 23: 148-53.
50. Oygarden H, Fromm A, Sand KM, Eide GE, Thomassen L, Naess H, Waje-Andreassen U. Can the cardiovascular family history reported by our patients be trusted? The Norwegian Stroke in the Young Study. *Eur J Neurol* 2016; 23: 154-9.
51. Yan Z, Liang Y, Shi J, Cai C, Jiang H, Song A, Qiu C. Carotid stenosis and cognitive impairment amongst older Chinese adults living in a rural area: a population-based study. *Eur J Neurol* 2016; 23: 201-4.
52. Park JH, Ovbiagele B. Relationship of functional disability after a recent stroke with recurrent stroke risk. *Eur J Neurol* 2016; 23: 361-7.
53. Bonner B, Pillai R, Sarma PS, Lipska KJ, Pandian J, Sylaja PN. Factors predictive of return to work after stroke in patients with mild-moderate disability in India. *Eur J Neurol* 2016; 23: 548-53.
54. Herweh C, Griebel M, Geisbusch C, Szabo K, Neumaier-Probst E, Hennerici MG, Bendszus M, Ringleb PA, Nagel S. Frequency and temporal profile of recanalization after cerebral vein and sinus thrombosis. *Eur J Neurol* 2016; 23: 681-7.
55. Ludemann-Podubecka J, Bosl K, Nowak DA. Inhibition of the contralesional dorsal premotor cortex improves motor function of the affected hand following stroke. *Eur J Neurol* 2016; 23: 823-30.

56. Frusch KJ, Houben R, Schreuder FH, Postma AA, Staals J. Association between eye position on brain scan and hospital mortality in acute intracerebral hemorrhage. *Eur J Neurol* 2016; 23: 831-5.
57. Jabbarli R, Bohrer AM, Pierscianek D, Muller D, Wrede KH, Dammann P, El HN, Ozkan N, Sure U, Muller O. The CHES score: a simple tool for early prediction of shunt dependency after aneurysmal subarachnoid hemorrhage. *Eur J Neurol* 2016; 23: 912-8.
58. Galovic M, Leisi N, Muller M, Weber J, Tettenborn B, Brugger F, Abela E, Weder B, Kagi G. Neuroanatomical correlates of tube dependency and impaired oral intake after hemispheric stroke. *Eur J Neurol* 2016; 23: 926-34.
59. Lu D, Ren S, Zhang J, Sun D. Vascular risk factors aggravate cognitive impairment in first-ever young ischaemic stroke patients. *Eur J Neurol* 2016; 23: 940-7.
60. Doeltgen SH, Omari TI. Correlating stroke lesion location with clinical outcomes - an example from deglutition research. *Eur J Neurol* 2016; 23: 1139-40.
61. Maaijwee NA, Tendolkar I, Rutten-Jacobs LC, Arntz RM, Schaapsmeeders P, Dorresteyn LD, Schoonderwaldt HC, van Dijk EJ, de Leeuw FE. Long-term depressive symptoms and anxiety after transient ischaemic attack or ischaemic stroke in young adults. *Eur J Neurol* 2016; 23: 1262-8.
62. Khajeh L, Ribbers GM, Heijenbrok-Kal MH, Blijdorp K, Dippel DW, Sneekes EM, van den Berg-Emons HJ, van der Lely AJ, Neggers SJ, van KF. The effect of hypopituitarism on fatigue after subarachnoid hemorrhage. *Eur J Neurol* 2016; 23: 1269-74.
63. Liu KP, Balderi K, Leung TL, Yue AS, Lam NC, Cheung JT, Fong SS, Sum CM, Bissett M, Rye R, Mok VC. A randomized controlled trial of self-regulated modified constraint-induced movement therapy in sub-acute stroke patients. *Eur J Neurol* 2016; 23: 1351-60.
64. Busch MA, Hoffmann O, Einhaupl KM, Masuhr F. Outcome of heparin-treated patients with acute cerebral venous sinus thrombosis: influence of the temporal pattern of intracerebral haemorrhage. *Eur J Neurol* 2016; 23: 1387-92.
65. Ranchet M, Akinwuntan AE, Tant M, Salch A, Neal E, Devos H. Fitness-to-drive agreements after stroke: medical versus practical recommendations. *Eur J Neurol* 2016; 23: 1408-14.
66. John G, Bardini C, Megevand P, Combescure C, Dallenbach P. Urinary incontinence as a predictor of death after new-onset stroke: a meta-analysis. *Eur J Neurol* 2016; 23: 1548-55.
67. Wasser K, Papanagiotou P, Brunner F, Hildebrandt H, Winterhalter M, Roth C, Kastrup A. Impact of ASPECTS on computed tomography angiography source images on outcome after thrombolysis or endovascular therapy in large vessel occlusions. *Eur J Neurol* 2016; 23: 1599-605.
68. Turner GM, Calvert M, Feltham MG, Ryan R, Marshall T. Ongoing impairments following transient ischaemic attack: retrospective cohort study. *Eur J Neurol* 2016; 23: 1642-50.
69. Ntaios G, Gioulekas F, Papavasileiou V, Strbian D, Michel P. ASTRAL, DRAGON and SEDAN scores predict stroke outcome more accurately than physicians. *Eur J Neurol* 2016; 23: 1651-7.
70. Yoon JA, Kim DY, Sohn MK, Lee J, Lee SG, Lee YS, Han EY, Joo MC, Oh GJ, Han J, Lee SW, Park M, Chang WH, Shin YI, Kim YH. Effect of stress hyperglycemia and intensive rehabilitation therapy in non-diabetic hemorrhagic stroke: Korean Stroke Cohort for Functioning and Rehabilitation. *Eur J Neurol* 2016; 23: 1658-65.

71. Du J, Tian L, Liu W, Hu J, Xu G, Ma M, Fan X, Ye R, Jiang Y, Yin Q, Zhu W, Xiong Y, Yang F, Liu X. Effects of repetitive transcranial magnetic stimulation on motor recovery and motor cortex excitability in patients with stroke: a randomized controlled trial. *Eur J Neurol* 2016; 23: 1666-72.
72. Gensicke H, Wicht A, Bill O, Zini A, Costa P, Kagi G, Stark R, Seiffge DJ, Traenka C, Peters N, Bonati LH, Giovannini G, De Marchis GM, Poli L, Polymeris A, Vanacker P, Sarikaya H, Lyrer PA, Pezzini A, Vandelli L, Michel P, Engelter ST. Impact of body mass index on outcome in stroke patients treated with intravenous thrombolysis. *Eur J Neurol* 2016; 23: 1705-12.

Multiple Sclerosis - General

73. Muhlert N, Penner IK. Understanding intellectual enrichment: how cognitive reserve impacts on hippocampal volume in multiple sclerosis. *Eur J Neurol* 2016; 23: 9-10.
74. Sumowski JF, Rocca MA, Leavitt VM, Riccitelli G, Sandry J, DeLuca J, Comi G, Filippi M. Searching for the neural basis of reserve against memory decline: intellectual enrichment linked to larger hippocampal volume in multiple sclerosis. *Eur J Neurol* 2016; 23: 39-44.
75. Leavitt VM, Sumowski JF. Characterizing cognitive impairment in multiple sclerosis: an essential step towards prediction and prevention. *Eur J Neurol* 2016; 23: 225-6.
76. Planche V, Gibelin M, Cregut D, Pereira B, Clavelou P. Cognitive impairment in a population-based study of patients with multiple sclerosis: differences between late relapsing-remitting, secondary progressive and primary progressive multiple sclerosis. *Eur J Neurol* 2016; 23: 282-9.
77. Yaldizli O, Penner IK, Yonekawa T, Naegelin Y, Kuhle J, Pardini M, Chard DT, Stippich C, Kira JI, Bendfeldt K, Amann M, Radue EW, Kappos L, Sprenger T. The association between olfactory bulb volume, cognitive dysfunction, physical disability and depression in multiple sclerosis. *Eur J Neurol* 2016; 23: 510-9.
78. Santoro M, Nociti V, De FC, Caprara A, Giordano R, Palomba N, Losavio F, Marra C, Patanella AK, Mirabella M, Gainotti G, Quaranta D. Depression in multiple sclerosis: effect of brain derived neurotrophic factor Val66Met polymorphism and disease perception. *Eur J Neurol* 2016; 23: 630-40.
79. Sacco R, Santangelo G, Stamenova S, Bisecco A, Bonavita S, Lavorgna L, Trojano L, D'Ambrosio A, Tedeschi G, Gallo A. Psychometric properties and validity of Beck Depression Inventory II in multiple sclerosis. *Eur J Neurol* 2016; 23: 744-50.
80. Granberg T, Hashim F, Andersen O, Sundal C, Karrenbauer VD. Hereditary diffuse leukoencephalopathy with spheroids - a volumetric and radiological comparison with multiple sclerosis patients and healthy controls. *Eur J Neurol* 2016; 23: 817-22.
81. Ayrygnac X, Menjot de CN, Menjot de CS, Carra-Dalliere C, Deverdun J, Corlobe A, Labauge P. Brain magnetic resonance imaging helps to differentiate atypical multiple sclerosis with cavitory lesions and vanishing white matter disease. *Eur J Neurol* 2016; 23: 995-1000.
82. McKay KA, Tremlett H, Zhu F, Kastrukoff L, Marrie RA, Kingwell E. A population-based study comparing multiple sclerosis clinic users and non-users in British Columbia, Canada. *Eur J Neurol* 2016; 23: 1093-100.
83. Zecca C, Riccitelli GC, Disanto G, Singh A, Digesu GA, Panicari L, Puccini F, Mattioli M, Tubaro A, Gobbi C. Urinary incontinence in multiple sclerosis: prevalence, severity and impact on patients' quality of life. *Eur J Neurol* 2016; 23: 1228-34.

84. Brenner P, Burkill S, Jokinen J, Hillert J, Bahmanyar S, Montgomery S. Multiple sclerosis and risk of attempted and completed suicide - a cohort study. *Eur J Neurol* 2016; 23: 1329-36.
85. Nourbakhsh B, Julian L, Waubant E. Fatigue and depression predict quality of life in patients with early multiple sclerosis: a longitudinal study. *Eur J Neurol* 2016; 23: 1482-6.

Multiple Sclerosis - Pathogenesis

86. Behrens JR, Rasche L, Giess RM, Pfuhl C, Wakonig K, Freitag E, Deuschle K, Bellmann-Strobl J, Paul F, Ruprecht K, Dorr J. Low 25-hydroxyvitamin D, but not the bioavailable fraction of 25-hydroxyvitamin D, is a risk factor for multiple sclerosis. *Eur J Neurol* 2016; 23: 62-7.
87. Mameli G, Madeddu G, Cossu D, Galleri G, Manetti R, Babudieri S, Mura MS, Sechi LA. Immune response induced by Epstein-Barr virus and Mycobacterium avium subsp. paratuberculosis peptides in current and past infectious mononucleosis: a risk for multiple sclerosis? *Eur J Neurol* 2016; 23: 140-7.
88. Goulden R, Riise T, Myhr KM, Pugliatti M, Wolfson C. Does low socioeconomic status in early life protect against multiple sclerosis? A multinational, case-control study. *Eur J Neurol* 2016; 23: 168-74.
89. Mowry EM, Pelletier D, Gao Z, Howell MD, Zamvil SS, Waubant E. Vitamin D in clinically isolated syndrome: evidence for possible neuroprotection. *Eur J Neurol* 2016; 23: 327-32.
90. de BL, Fraussen J, Villar LM, Alvarez-Cermeno JC, Van WB, van P, V, Stinissen P, Somers V. Anti-SPAG16 antibodies in primary progressive multiple sclerosis are associated with an elevated progression index. *Eur J Neurol* 2016; 23: 722-8.
91. Bos SD, Berge T, Celius EG, Harbo HF. From genetic associations to functional studies in multiple sclerosis. *Eur J Neurol* 2016; 23: 847-53.
92. Mollgaard M, Degn M, Sellebjerg F, Frederiksen JL, Modvig S. Cerebrospinal fluid chitinase-3-like 2 and chitotriosidase are potential prognostic biomarkers in early multiple sclerosis. *Eur J Neurol* 2016; 23: 898-905.
93. Wens I, Keytsman C, Deckx N, Cools N, Dalgas U, Eijnde BO. Brain derived neurotrophic factor in multiple sclerosis: effect of 24 weeks endurance and resistance training. *Eur J Neurol* 2016; 23: 1028-35.
94. Wergeland S, Myhr KM, Loken-Amsrud KI, Beiske AG, Bjerve KS, Hovdal H, Midgard R, Kvistad SS, Holmoy T, Riise T, Torkildsen O. Vitamin D, HLA-DRB1 and Epstein-Barr virus antibody levels in a prospective cohort of multiple sclerosis patients. *Eur J Neurol* 2016; 23: 1064-70.
95. Tremlett H, Fadrosch DW, Faruqi AA, Zhu F, Hart J, Roalstad S, Graves J, Lynch S, Waubant E. Gut microbiota in early pediatric multiple sclerosis: a case-control study. *Eur J Neurol* 2016; 23: 1308-21.
96. Pardini M, Botzkowski D, Muller S, Vehoff J, Kuhle J, Ruberte E, Wurfel J, Gass A, Valmaggia C, Tettenborn B, Putzki N, Yaldizli O. The association between retinal nerve fibre layer thickness and N-acetyl aspartate levels in multiple sclerosis brain normal-appearing white matter: a longitudinal study using magnetic resonance spectroscopy and optical coherence tomography. *Eur J Neurol* 2016; 23: 1769-74.

Multiple Sclerosis - Treatment

97. Dominguez-Mozo MI, Garcia-Montojo M, Arias-Leal A, Garcia-Martinez A, Santiago JL, Casanova I, Galan V, Arroyo R, Fernandez-Arquero M, Alvarez-Lafuente R. Monitoring the John Cunningham virus throughout natalizumab treatment in multiple sclerosis patients. *Eur J Neurol* 2016; 23: 182-9.
98. Radue EW, Sprenger T, Vollmer T, Giovannoni G, Gold R, Havrdova E, Selmaj K, Stefoski D, You X, Elkins J. Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis. *Eur J Neurol* 2016; 23: 412-5.
99. Lus G, Signoriello E, Maniscalco GT, Bonavita S, Signoriello S, Gallo C. Treatment withdrawal in relapsing-remitting multiple sclerosis: a retrospective cohort study. *Eur J Neurol* 2016; 23: 489-93.
100. Modolo GP, do Olival GS. Medication withdrawal in relapsing-remitting multiple sclerosis: why not? *Eur J Neurol* 2016; 23: 679-80.
101. Spelman T, Mekhael L, Burke T, Butzkueven H, Hodgkinson S, Havrdova E, Horakova D, Duquette P, Izquierdo G, Grand'Maison F, Grammond P, Barnett M, Lechner-Scott J, Alroughani R, Trojano M, Lugaresi A, Granella F, Pucci E, Vucic S. Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis. *Eur J Neurol* 2016; 23: 729-36.
102. Sorensen PS, Sellebjerg F, Lycke J, Farkkila M, Creange A, Lund CG, Schlupe M, Frederiksen JL, Stenager E, Pflieger C, Garde E, Kinnunen E, Marhardt K. Minocycline added to subcutaneous interferon beta-1a in multiple sclerosis: randomized RECYCLINE study. *Eur J Neurol* 2016; 23: 861-70.
103. Vennegoor A, van Rossum JA, Leurs C, Wattjes MP, Rispens T, Murk JL, Uitdehaag BM, Killestein J. High cumulative JC virus seroconversion rate during long-term use of natalizumab. *Eur J Neurol* 2016; 23: 1079-85.
104. Zivadinov R, Hojnacki D, Bergsland N, Kennedy C, Hagemeyer J, Melia R, Ramasamy DP, Durfee J, Carl E, Dwyer MG, Weinstock-Guttman B. Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years. *Eur J Neurol* 2016; 23: 1101-9.

Parkinson's Disease - General

105. Bang HM, Johnsen EL, Sunde N, Vase A, Gjelstrup MC, Ostergaard K. Surviving 10 years with deep brain stimulation for Parkinson's disease--a follow-up of 79 patients. *Eur J Neurol* 2016; 23: 53-61.
106. Logroscino G. A community study outlines how to prevent Parkinson's disease motor complications in the clinic. *Eur J Neurol* 2016; 23: 231-2.
107. Schneider SA, Boettner M, Alexoudi A, Zorenkov D, Deuschl G, Wedel T. Can we use peripheral tissue biopsies to diagnose Parkinson's disease? A review of the literature. *Eur J Neurol* 2016; 23: 247-61.
108. Scott NW, Macleod AD, Counsell CE. Motor complications in an incident Parkinson's disease cohort. *Eur J Neurol* 2016; 23: 304-12.
109. Caviness JN, Utianski RL, Hentz JG, Beach TG, Dugger BN, Shill HA, Driver-Dunckley ED, Sabbagh MN, Mehta S, Adler CH. Differential spectral quantitative electroencephalography patterns between control and Parkinson's disease cohorts. *Eur J Neurol* 2016; 23: 387-92.
110. Kimber T, Antonini A. Peripheral neuropathy and levodopa therapy in Parkinson disease: novel insights. *Eur J Neurol* 2016; 23: 435-6.

111. Merola A, Romagnolo A, Zibetti M, Bernardini A, Cocito D, Lopiano L. Peripheral neuropathy associated with levodopa-carbidopa intestinal infusion: a long-term prospective assessment. *Eur J Neurol* 2016; 23: 501-9.
112. Svensson E, Farkas DK, Gradus JL, Lash TL, Sorensen HT. Adjustment disorder and risk of Parkinson's disease. *Eur J Neurol* 2016; 23: 751-6.
113. Rizos A, Sauerbier A, Antonini A, Weintraub D, Martinez-Martin P, Kessel B, Henriksen T, Falup-Pecurariu C, Silverdale M, Durner G, Rokenes KK, Grilo M, Odin P, Chaudhuri KR. A European multicentre survey of impulse control behaviours in Parkinson's disease patients treated with short- and long-acting dopamine agonists. *Eur J Neurol* 2016; 23: 1255-61.
114. Antonini A, Chaudhuri KR, Boroojerdi B, Asgharnejad M, Bauer L, Grieger F, Weintraub D. Impulse control disorder related behaviours during long-term rotigotine treatment: a post hoc analysis. *Eur J Neurol* 2016; 23: 1556-65.

Parkinson's Disease - Pathogenesis

115. Reimao S, Ferreira S, Nunes RG, Pita LP, Neutel D, Abreu D, Goncalves N, Campos J, Ferreira JJ. Magnetic resonance correlation of iron content with neuromelanin in the substantia nigra of early-stage Parkinson's disease. *Eur J Neurol* 2016; 23: 368-74.
116. Pilotto A, Schulte C, Hauser AK, Biskup S, Munz M, Brockmann K, Schaeffer E, Synofzik M, Maetzler W, Suenkel U, Srulijes K, Gasser T, Berg D. GBA-associated parkinsonism and dementia: beyond alpha-synucleinopathies? *Eur J Neurol* 2016; 23: 520-6.
117. Liou CW, Chuang JH, Chen JB, Tiao MM, Wang PW, Huang ST, Huang TL, Lee WC, Weng SW, Huang PH, Chen SD, Chen RS, Lu CS, Lin TK. Mitochondrial DNA variants as genetic risk factors for Parkinson disease. *Eur J Neurol* 2016; 23: 1289-300.

Parkinson's Disease - NMS

118. Prakash KM, Nadkarni NV, Lye WK, Yong MH, Tan EK. The impact of non-motor symptoms on the quality of life of Parkinson's disease patients: a longitudinal study. *Eur J Neurol* 2016; 23: 854-60.
119. Dahms C, Guenther A, Schwab M, Schultze T, Nowack S, Hoyer D, Ehrhardt J, Witte OW, Mayer G, Rupprecht S. Dysautonomia in prodromal alpha-synucleinopathy: peripheral versus central autonomic degeneration. *Eur J Neurol* 2016; 23: 878-90.
120. Wen MC, Chan LL, Tan LC, Tan EK. Depression, anxiety, and apathy in Parkinson's disease: insights from neuroimaging studies. *Eur J Neurol* 2016; 23: 1001-19.
121. Klingelhoefer L, Rizos A, Sauerbier A, McGregor S, Martinez-Martin P, Reichmann H, Horne M, Chaudhuri KR. Night-time sleep in Parkinson's disease - the potential use of Parkinson's KinetiGraph: a prospective comparative study. *Eur J Neurol* 2016; 23: 1275-88.
122. Foki T, Vanbellinghen T, Lungu C, Pirker W, Bohlhalter S, Nyffeler T, Kraemmer J, Haubenberger D, Fischmeister FP, Auff E, Hallett M, Beisteiner R. Limb-kinetic apraxia affects activities of daily living in Parkinson's disease: a multi-center study. *Eur J Neurol* 2016; 23: 1301-7.
123. Colosimo C, Bhidayasiri R. Nonmotor symptoms in Parkinson's disease: are we still waiting for the honeymoon? *Eur J Neurol* 2016; 23: 1595-6.
124. Stirpe P, Hoffman M, Badiali D, Colosimo C. Constipation: an emerging risk factor for Parkinson's disease? *Eur J Neurol* 2016; 23: 1606-13.

125. Erro R, Picillo M, Vitale C, Amboni M, Moccia M, Santangelo G, Pellecchia MT, Barone P. The non-motor side of the honeymoon period of Parkinson's disease and its relationship with quality of life: a 4-year longitudinal study. *Eur J Neurol* 2016; 23: 1673-9.

Other Movement Disorders

126. Lee MJ, Shin JH, Seoung JK, Lee JH, Yoon U, Oh JH, Jung DS, Kim EJ. Cognitive impairments associated with morphological changes in cortical and subcortical structures in multiple system atrophy of the cerebellar type. *Eur J Neurol* 2016; 23: 92-100.
127. Preda F, Cavandoli C, Lettieri C, Pilleri M, Antonini A, Eleopra R, Mondani M, Martinuzzi A, Sarubbo S, Ghisellini G, Trezza A, Cavallo MA, Landi A, Sensi M. Switching from constant voltage to constant current in deep brain stimulation: a multicenter experience of mixed implants for movement disorders. *Eur J Neurol* 2016; 23: 190-5.
128. Ueha R, Nito T, Sakamoto T, Yamauchi A, Tsunoda K, Yamasoba T. Post-operative swallowing in multiple system atrophy. *Eur J Neurol* 2016; 23: 393-400.
129. Macerollo A, Chen JC, Parees I, Sadnicka A, Kassavetis P, Bhatia KP, Kilner JM, Rothwell JC, Edwards MJ. Abnormal movement-related suppression of sensory evoked potentials in upper limb dystonia. *Eur J Neurol* 2016; 23: 562-8.
130. Valadas A, Contarino MF, Albanese A, Bhatia KP, Falup-Pecurariu C, Forsgren L, Friedman A, Giladi N, Hutchinson M, Kostic VS, Krauss JK, Lokkegaard A, Marti MJ, Milanov I, Pirtosek Z, Relja M, Skorvanek M, Stamelou M, Stepens A, Tamas G, Taravari A, Tzoulis C, Vandenberghe W, Vidailhet M, Ferreira JJ, Tijssen MA. Management of dystonia in Europe: a survey of the European network for the study of the dystonia syndromes. *Eur J Neurol* 2016; 23: 772-9.
131. Deuschl G. Multiple non-parkinsonian rest tremors: dystonic rest tremor is the next candidate. *Eur J Neurol* 2016; 23: 837-8.
132. Gigante AF, Berardelli A, Defazio G. Rest tremor in idiopathic adult-onset dystonia. *Eur J Neurol* 2016; 23: 935-9.
133. van Oosterhout WP, van Someren EJ, Louter MA, Schoonman GG, Lammers GJ, Rijsman RM, Ferrari MD, Terwindt GM. Restless legs syndrome in migraine patients: prevalence and severity. *Eur J Neurol* 2016; 23: 1110-6.
134. Battistella G, Fuertinger S, Fleysler L, Ozelius LJ, Simonyan K. Cortical sensorimotor alterations classify clinical phenotype and putative genotype of spasmodic dysphonia. *Eur J Neurol* 2016; 23: 1517-27.

Alzheimer's Disease and Other Dementias

135. Zetterberg H, Mattsson N. Cerebral amyloid burden and Alzheimer's disease subtypes--does localization information matter? *Eur J Neurol* 2016; 23: 233-4.
136. Willette A. Does metabolic syndrome impact cognition and emotion in Alzheimer's disease? *Eur J Neurol* 2016; 23: 237-8.
137. Jung Y, Whitwell JL, Duffy JR, Strand EA, Machulda MM, Senjem ML, Jack CR, Lowe VJ, Josephs KA. Regional beta-amyloid burden does not correlate with cognitive or language deficits in Alzheimer's disease presenting as aphasia. *Eur J Neurol* 2016; 23: 313-9.

138. Hishikawa N, Fukui Y, Sato K, Kono S, Yamashita T, Ohta Y, Deguchi K, Abe K. Cognitive and affective functions in Alzheimer's disease patients with metabolic syndrome. *Eur J Neurol* 2016; 23: 339-45.
139. Montero-Odasso M. Gait as a biomarker of cognitive impairment and dementia syndromes. *Quo vadis? Eur J Neurol* 2016; 23: 437-8.
140. Allali G, Annweiler C, Blumen HM, Callisaya ML, De Cock AM, Kressig RW, Srikanth V, Steinmetz JP, Verghese J, Beauchet O. Gait phenotype from mild cognitive impairment to moderate dementia: results from the GOOD initiative. *Eur J Neurol* 2016; 23: 527-41.
141. Vannier-Nitenberg C, Dauphinot V, Bongue B, Sass C, Bathsavanis A, Rouch I, Deville N, Beauchet O, Krolak-Salmon P, Fantino B. Performance of cognitive tests, individually and combined, for the detection of cognitive disorders amongst community-dwelling elderly people with memory complaints: the EVATEM study. *Eur J Neurol* 2016; 23: 554-61.
142. Kitagawa K, Miwa K, Okazaki S, Sakaguchi M, Mochizuki H. Serum high-molecular-weight adiponectin level and incident dementia in patients with vascular risk factors. *Eur J Neurol* 2016; 23: 641-7.
143. Miwa K, Okazaki S, Sakaguchi M, Mochizuki H, Kitagawa K. Interleukin-6, interleukin-6 receptor gene variant, small-vessel disease and incident dementia. *Eur J Neurol* 2016; 23: 656-63.
144. Bisenius S, Neumann J, Schroeter ML. Validating new diagnostic imaging criteria for primary progressive aphasia via anatomical likelihood estimation meta-analyses. *Eur J Neurol* 2016; 23: 704-12.
145. Cohen OS, Kimiagar I, Korczyn AD, Nitsan Z, Appel S, Hoffmann C, Rosenmann H, Kahana E, Chapman J. Unusual presentations in patients with E200K familial Creutzfeldt-Jakob disease. *Eur J Neurol* 2016; 23: 871-7.
146. Ye BS, Lee WW, Ham JH, Lee JJ, Lee PH, Sohn YH. Does serum uric acid act as a modulator of cerebrospinal fluid Alzheimer's disease biomarker related cognitive decline? *Eur J Neurol* 2016; 23: 948-57.
147. Yilmaz R, Behnke S, Liepelt-Scarfone I, Roeben B, Pausch C, Runkel A, Heinzel S, Niebler R, Suenkel U, Eschweiler GW, Maetzler W, Berg D. Substantia nigra hyperechogenicity is related to decline in verbal memory in healthy elderly adults. *Eur J Neurol* 2016; 23: 973-8.
148. Krolak-Salmon P, Roubaud C, Finne-Soveri H, Riolacci-Dhoyen N, Richard G, Rouch I, Leperre-Desplanques A, Dauphinot V. Evaluation of a mobile team dedicated to behavioural disorders as recommended by the Alzheimer Cooperative Valuation in Europe joint action: observational cohort study. *Eur J Neurol* 2016; 23: 979-88.
149. Riba-Llena I, Nafria C, Mundet X, Lopez-Rueda A, Fernandez-Cortinas I, Jarca CI, Jimenez-Balado J, Domingo M, Tovar JL, Orfila F, Pujadas F, Alvarez-Sabin J, Maisterra O, Montaner J, Delgado P. Assessment of enlarged perivascular spaces and their relation to target organ damage and mild cognitive impairment in patients with hypertension. *Eur J Neurol* 2016; 23: 1044-50.
150. Gmitterova K, Heinemann U, Krasnianski A, Gawinecka J, Zerr I. Cerebrospinal fluid markers in the differentiation of molecular subtypes of sporadic Creutzfeldt-Jakob disease. *Eur J Neurol* 2016; 23: 1126-33.

151. Valdes HM, Allerhand M, Glatz A, Clayson L, Munoz MS, Gow A, Royle N, Bastin M, Starr J, Deary I, Wardlaw J. Do white matter hyperintensities mediate the association between brain iron deposition and cognitive abilities in older people? *Eur J Neurol* 2016; 23: 1202-9.
152. Delphin-Combe F, Bathsavanis A, Rouch I, Liles T, Vannier-Nitenberg C, Fantino B, Dauphinot V, Krolak-Salmon P. Relationship between anxiety and cognitive performance in an elderly population with a cognitive complaint. *Eur J Neurol* 2016; 23: 1210-7.
153. Favaretto S, Walter U, Baracchini C, Pompanin S, Busse C, Zorzi G, Ermani M, Cagnin A. Accuracy of transcranial brain parenchyma sonography in the diagnosis of dementia with Lewy bodies. *Eur J Neurol* 2016; 23: 1322-8.
154. Zhang JB, Li MF, Zhang HX, Li ZG, Sun HR, Zhang JS, Wang PF. Association of serum vascular endothelial growth factor levels and cerebral microbleeds in patients with Alzheimer's disease. *Eur J Neurol* 2016; 23: 1337-42.
155. Frahm-Falkenberg S, Ibsen R, Kjellberg J, Jennum P. Health, social and economic consequences of dementias: a comparative national cohort study. *Eur J Neurol* 2016; 23: 1400-7.
156. Ma C, Zhang Y, Li X, Zhang J, Chen K, Liang Y, Chen Y, Liu Z, Zhang Z. Is there a significant interaction effect between apolipoprotein E rs405509 T/T and epsilon4 genotypes on cognitive impairment and gray matter volume? *Eur J Neurol* 2016; 23: 1415-25.
157. Zhang N, Yang Y, Wang A, Cao Y, Li J, Yang Y, Zhang K, Zhang W, Wu S, Wang Z, Zhu M, Zhang Y, Wu S, Wang C, Zhao X. Association of ideal cardiovascular health metrics and cognitive functioning: the APAC study. *Eur J Neurol* 2016; 23: 1447-54.
158. Nakatani E, Kanatani Y, Kaneda H, Nagai Y, Teramukai S, Nishimura T, Zhou B, Kojima S, Kono H, Fukushima M, Kitamoto T, Mizusawa H. Specific clinical signs and symptoms are predictive of clinical course in sporadic Creutzfeldt-Jakob disease. *Eur J Neurol* 2016; 23: 1455-62.
159. Boublay N, Schott AM, Krolak-Salmon P. Neuroimaging correlates of neuropsychiatric symptoms in Alzheimer's disease: a review of 20 years of research. *Eur J Neurol* 2016; 23: 1500-9.
160. Jiang Y, Zhang YF, Liu M, Ma LL, Peng FH, Huang QL, Ma XM, Chen XH. Syphilitic dementia and lipid metabolism. *Eur J Neurol* 2016; 23: 1541-7.
161. Jones C, Busse M, Quinn L, Dawes H, Drew C, Kelson M, Hood K, Rosser A, Edwards RT. The societal cost of Huntington's disease: are we underestimating the burden? *Eur J Neurol* 2016; 23: 1588-90.
162. Mura T, Amieva H, Goldberg M, Dartigues JF, Ankri J, Zins M, Berr C. Effect size for the main cognitive function determinants in a large cross-sectional study. *Eur J Neurol* 2016; 23: 1614-26.

Motor Neurone Disease (Amyotrophic Lateral Sclerosis)

163. Ludolph AC. The TUDCA trial--innovative trial designs for amyotrophic lateral sclerosis drugs? *Eur J Neurol* 2016; 23: 11-2.
164. Elia AE, Lalli S, Monsurro MR, Sagnelli A, Taiello AC, Reggiori B, La B, V, Tedeschi G, Albanese A. Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis. *Eur J Neurol* 2016; 23: 45-52.
165. Chio A, Swash M. Alcohol and amyotrophic lateral sclerosis: a possible neuroprotective effect. *Eur J Neurol* 2016; 23: 221-2.

166. Ji J, Sundquist J, Sundquist K. Association of alcohol use disorders with amyotrophic lateral sclerosis: a Swedish national cohort study. *Eur J Neurol* 2016; 23: 270-5.
167. Blasco H, Nadal-Desbarats L, Pradat PF, Gordon PH, Madji HB, Patin F, Veyrat-Durebex C, Mavel S, Beltran S, Emond P, Andres CR, Corcia P. Biomarkers in amyotrophic lateral sclerosis: combining metabolomic and clinical parameters to define disease progression. *Eur J Neurol* 2016; 23: 346-53.
168. Dalla BE, Lombardi R, Porretta-Serapiglia C, Ciano C, Gellera C, Pensato V, Cazzato D, Lauria G. Amyotrophic lateral sclerosis causes small fiber pathology. *Eur J Neurol* 2016; 23: 416-20.
169. Blasco H, Patin F, Madji HB, Gordon PH, Vourc'h P, Andres CR, Corcia P. Metabolomics in amyotrophic lateral sclerosis: how far can it take us? *Eur J Neurol* 2016; 23: 447-54.
170. Marin B, Beghi E, Vial C, Bernard E, Lautrette G, Clavelou P, Guy N, Lemasson G, Debruxelles S, Cintas P, Antoine JC, Camdessanche JP, Logroscino G, Preux PM, Couratier P. Evaluation of the application of the European guidelines for the diagnosis and clinical care of amyotrophic lateral sclerosis (ALS) patients in six French ALS centres. *Eur J Neurol* 2016; 23: 787-95.
171. Caga J, Turner MR, Hsieh S, Ahmed RM, Devenney E, Ramsey E, Zoing MC, Mioshi E, Kiernan MC. Apathy is associated with poor prognosis in amyotrophic lateral sclerosis. *Eur J Neurol* 2016; 23: 891-7.
172. Nicoletti A, Vasta R, Venti V, Mostile G, Lo FS, Patti F, Scillieri R, De CD, Volanti P, Marziolo R, Maimone D, Fiore M, Ferrante M, Zappia M. The epidemiology of amyotrophic lateral sclerosis in the Mount Etna region: a possible pathogenic role of volcanogenic metals. *Eur J Neurol* 2016; 23: 964-72.
173. Rafiq MK, Lee E, Bradburn M, McDermott CJ, Shaw PJ. Creatine kinase enzyme level correlates positively with serum creatinine and lean body mass, and is a prognostic factor for survival in amyotrophic lateral sclerosis. *Eur J Neurol* 2016; 23: 1071-8.
174. Tortelli R, Copetti M, Panza F, Fontana A, Cortese R, Capozzo R, Introna A, D'Errico E, Zoccolella S, Arcuti S, Seripa D, Simone IL, Logroscino G. Time to generalization and prediction of survival in patients with amyotrophic lateral sclerosis: a retrospective observational study. *Eur J Neurol* 2016; 23: 1117-25.
175. Schuster C, Elamin M, Hardiman O, Bede P. The segmental diffusivity profile of amyotrophic lateral sclerosis associated white matter degeneration. *Eur J Neurol* 2016; 23: 1361-71.
176. Ferraro D, Consonni D, Fini N, Fasano A, Del GC, Mandrioli J. Amyotrophic lateral sclerosis: a comparison of two staging systems in a population-based study. *Eur J Neurol* 2016; 23: 1426-32.

Epilepsy

177. Sierra-Marcos A, Carreno M, Setoain X, Lopez-Rueda A, Aparicio J, Donaire A, Bargallo N. Accuracy of arterial spin labeling magnetic resonance imaging (MRI) perfusion in detecting the epileptogenic zone in patients with drug-resistant neocortical epilepsy: comparison with electrophysiological data, structural MRI, SISCOM and FDG-PET. *Eur J Neurol* 2016; 23: 160-7.
178. Verrotti A, Laino D, Rinaldi VE, Suppiej A, Giordano L, Toldo I, Margari L, Parisi P, Rizzo R, Matricardi S, Cusmai R, Grosso S, Gaggero R, Zamponi N, Pavone P, Capovilla G, Rauchenzauner M, Cerminara C, Di GG, Esposito M, Striano P, Savasta S, Coppola G, Siliquini S, Operto F, Belcastro V, Ragona F, Marseglia GL, Spalice A. Clinical dissection of childhood occipital epilepsy of Gastaut and prognostic implication. *Eur J Neurol* 2016; 23: 241-6.

179. Baldin E, Hauser WA. Can the predictive value of epileptiform electroencephalography abnormalities be assessed by a meta-analysis? *Eur J Neurol* 2016; 23: 431-2.
180. Bouma HK, Labos C, Gore GC, Wolfson C, Keezer MR. The diagnostic accuracy of routine electroencephalography after a first unprovoked seizure. *Eur J Neurol* 2016; 23: 455-63.
181. Kothare S, Kaleyias J. Is treatment in adults with intellectual and developmental disability also suffering from epilepsy different from adults with uncomplicated epilepsy? *Eur J Neurol* 2016; 23: 1141-2.
182. Doran Z, Shankar R, Keezer MR, Dale C, McLean B, Kerr MP, Devapriam J, Craig J, Sander JW. Managing anti-epileptic drug treatment in adult patients with intellectual disability: a serious conundrum. *Eur J Neurol* 2016; 23: 1152-7.
183. Hikmat O, Tzoulis C, Knappskog PM, Johansson S, Boman H, Sztromwasser P, Lien E, Brodtkorb E, Ghezzi D, Bindoff LA. ADCK3 mutations with epilepsy, stroke-like episodes and ataxia: a POLG mimic? *Eur J Neurol* 2016; 23: 1188-94.
184. Giussani G, Canelli V, Bianchi E, Erba G, Franchi C, Nobili A, Sander JW, Beghi E. Long-term prognosis of epilepsy, prognostic patterns and drug resistance: a population-based study. *Eur J Neurol* 2016; 23: 1218-27.
185. Theitler J, Dassa D, Gelernter I, Gandelman-Marton R. Is it time for individualized testing in the electroencephalogram (EEG) laboratory? *Eur J Neurol* 2016; 23: 1477-81.
186. Gonzalez-Cuevas M, Santamarina E, Toledo M, Quintana M, Sala J, Sueiras M, Guzman L, Salas-Puig J. A new clinical score for the prognosis of status epilepticus in adults. *Eur J Neurol* 2016; 23: 1534-40.
187. Jayalakshmi S, Vooturi S. Outcome scores in status epilepticus - predicting the complex clinical situation. *Eur J Neurol* 2016; 23: 1591-2.
188. Vecchio F. The importance of the family heritage in epilepsy. *Eur J Neurol* 2016; 23: 1694-5.
189. Giovagnoli AR, Parente A, Didato G, Manfredi V, Deleo F, Tringali G, Villani F. The course of language functions after temporal lobe epilepsy surgery: a prospective study. *Eur J Neurol* 2016; 23: 1713-21.
190. Bharath RD, Chaitanya G, Panda R, Raghavendra K, Sinha S, Sahoo A, Gohel S, Biswal BB, Satishchandra P. Reduced small world brain connectivity in probands with a family history of epilepsy. *Eur J Neurol* 2016; 23: 1729-37.

Neuromuscular

191. Rinaldi S. Complex antibodies provide a simple explanation for the plurality of clinical presentations in the Guillain Barre syndromes. *Eur J Neurol* 2016; 23: 235-6.
192. Fukami Y, Wong AH, Funakoshi K, Safri AY, Shahrizaila N, Yuki N. Anti-GQ1b antibody syndrome: anti-ganglioside complex reactivity determines clinical spectrum. *Eur J Neurol* 2016; 23: 320-6.
193. Arumugam T, Razali SN, Vethakkan SR, Rozalli FI, Shahrizaila N. Relationship between ultrasonographic nerve morphology and severity of diabetic sensorimotor polyneuropathy. *Eur J Neurol* 2016; 23: 354-60.

194. Servelhere KR, Faber I, Saute JA, Moscovich M, D'Abreu A, Jardim LB, Teive HA, Lopes-Cendes I, Franca MC, Jr. Non-motor symptoms in patients with hereditary spastic paraplegia caused by SPG4 mutations. *Eur J Neurol* 2016; 23: 408-11.
195. Bae JS, Kim YJ, Kim JK. Diabetes mellitus exacerbates the clinical and electrophysiological features of Guillain-Barre syndrome. *Eur J Neurol* 2016; 23: 439-46.
196. Gadalla SM, Pfeiffer RM, Kristinsson SY, Bjorkholm M, Landgren O, Greene MH. Brain tumors in patients with myotonic dystrophy: a population-based study. *Eur J Neurol* 2016; 23: 542-7.
197. Nodera H, Takamatsu N, Matsui N, Mori A, Terasawa Y, Shimatani Y, Osaki Y, Maruyama K, Izumi Y, Kaji R. Intramuscular dissociation of echogenicity in the triceps surae characterizes sporadic inclusion body myositis. *Eur J Neurol* 2016; 23: 588-96.
198. Ten DL, van der Kooi AJ, Verhamme C, Wattjes MP, de VM. Muscle imaging in inherited and acquired muscle diseases. *Eur J Neurol* 2016; 23: 688-703.
199. Rydning SL, Wedding IM, Koht J, Chawla M, Oye AM, Sheng Y, Vigeland MD, Selmer KK, Tallaksen CM. A founder mutation p.H701P identified as a major cause of SPG7 in Norway. *Eur J Neurol* 2016; 23: 763-71.
200. Marrali G, Salamone P, Casale F, Fuda G, Cugnasco P, Caorsi C, Amoroso A, Calvo A, Lopiano L, Cocito D, Chio A. NADPH oxidase 2 (NOX2) enzyme activation in patients with chronic inflammatory demyelinating polyneuropathy. *Eur J Neurol* 2016; 23: 958-63.
201. Hilton-Jones D. Bending over forwards - to make a diagnosis. *Eur J Neurol* 2016; 23: 993-4.
202. Luigetti M, Sauchelli D, Primiano G, Cuccagna C, Bernardo D, Lo MM, Servidei S. Peripheral neuropathy is a common manifestation of mitochondrial diseases: a single-centre experience. *Eur J Neurol* 2016; 23: 1020-7.
203. Sekiguchi Y, Mori M, Misawa S, Sawai S, Yuki N, Beppu M, Kuwabara S. How often and when Fisher syndrome is overlapped by Guillain-Barre syndrome or Bickerstaff brainstem encephalitis? *Eur J Neurol* 2016; 23: 1058-63.
204. Chanson JB, Lannes B, Echaniz-Laguna A. Is deltoid muscle biopsy useful in isolated camptocormia? A prospective study. *Eur J Neurol* 2016; 23: 1086-92.
205. Bertolin C, Querin G, Da RE, Sagnelli A, Bello L, Cao M, Muscas M, Pennuto M, Ermani M, Pegoraro E, Mariotti C, Gellera C, Hanna MG, Pareyson D, Fratta P, Soraru G. No effect of AR polyG polymorphism on spinal and bulbar muscular atrophy phenotype. *Eur J Neurol* 2016; 23: 1134-6.
206. Draak TH, Gorson KC, Vanhoutte EK, van Nes SI, van Doorn PA, Cornblath DR, van den Berg LH, Faber CG, Merkies IS. Correlation of the patient's reported outcome Inflammatory-RODS with an objective metric in immune-mediated neuropathies. *Eur J Neurol* 2016; 23: 1248-53.
207. Padua L, Pazzaglia C, Pareyson D, Schenone A, Aiello A, Fabrizi GM, Cavallaro T, Santoro L, Manganelli F, Gemignani F, Vitetta F, Quattrone A, Mazzeo A, Russo M, Vita G. Novel outcome measures for Charcot-Marie-Tooth disease: validation and reliability of the 6-min walk test and StepWatch() Activity Monitor and identification of the walking features related to higher quality of life. *Eur J Neurol* 2016; 23: 1343-50.

208. Xie Y, Meng Y, Li HF, Hong Y, Sun L, Zhu X, Yue YX, Gao X, Wang S, Li Y, Kusner LL, Kaminski HJ. GR gene polymorphism is associated with inter-subject variability in response to glucocorticoids in patients with myasthenia gravis. *Eur J Neurol* 2016; 23: 1372-9.
209. Winblad S, Samuelsson L, Lindberg C, Meola G. Cognition in myotonic dystrophy type 1: a 5-year follow-up study. *Eur J Neurol* 2016; 23: 1471-6.
210. Manganelli F, Pisciotta C, Reilly MM, Tozza S, Schenone A, Fabrizi GM, Cavallaro T, Vita G, Padua L, Gemignani F, Laura M, Hughes RA, Solari A, Pareyson D, Santoro L. Nerve conduction velocity in CMT1A: what else can we tell? *Eur J Neurol* 2016; 23: 1566-71.
211. Tessa A, Battini R, Rubegni A, Storti E, Marini C, Galatolo D, Pasquariello R, Santorelli FM. Identification of mutations in AP4S1/SPG52 through next generation sequencing in three families. *Eur J Neurol* 2016; 23: 1580-7.
212. Richman DP. Lipoprotein-like receptor 4 antibodies in myasthenia gravis: pathogenic or protective. *Eur J Neurol* 2016; 23: 1593-4.
213. Nikolic AV, Bojic SD, Rakocevic Stojanovic VM, Basta IZ, Lavrnjc DV. Electrophysiological findings in patients with low density lipoprotein receptor related protein 4 positive myasthenia gravis. *Eur J Neurol* 2016; 23: 1635-41.

Trauma

214. Konigs M, Engenhorst PJ, Oosterlaan J. Intelligence after traumatic brain injury: meta-analysis of outcomes and prognosis. *Eur J Neurol* 2016; 23: 21-9.
215. Wong JC, Linn KA, Shinohara RT, Mateen FJ. Traumatic brain injury in Africa in 2050: a modeling study. *Eur J Neurol* 2016; 23: 382-6.

Neuro-Inflammation

216. Matsuzono K, Honda H, Sato K, Morihara R, Deguchi K, Hishikawa N, Yamashita T, Kono S, Ohta Y, Iwaki T, Abe K. 'PrP systemic deposition disease': clinical and pathological characteristics of novel familial prion disease with 2-bp deletion in codon 178. *Eur J Neurol* 2016; 23: 196-200.
217. Monson N. Antinuclear antibodies in neuromyelitis optica: guardians of the brain? *Eur J Neurol* 2016; 23: 223-4.
218. Masuda H, Mori M, Uzawa A, Muto M, Uchida T, Kuwabara S. Serum antinuclear antibody may be associated with less severe disease activity in neuromyelitis optica. *Eur J Neurol* 2016; 23: 276-81.
219. van Pelt ED, Wong YY, Ketelslegers IA, Hamann D, Hintzen RQ. Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands. *Eur J Neurol* 2016; 23: 580-7
220. Wang W, Li JM, Hu FY, Wang R, Hong Z, He L, Zhou D. Anti-NMDA receptor encephalitis: clinical characteristics, predictors of outcome and the knowledge gap in southwest China. *Eur J Neurol* 2016; 23: 621-9.
221. Constantinescu R, Krysl D, Bergquist F, Andren K, Malmestrom C, Asztely F, Axelsson M, Menachem EB, Blennow K, Rosengren L, Zetterberg H. Cerebrospinal fluid markers of neuronal and glial cell damage to monitor disease activity and predict long-term outcome in patients with autoimmune encephalitis. *Eur J Neurol* 2016; 23: 796-806.

222. Sainz-de-la-Maza S, Casado JL, Perez-Elias MJ, Moreno A, Quereda C, Moreno S, Corral I. Incidence and prognosis of immune reconstitution inflammatory syndrome in HIV-associated progressive multifocal leucoencephalopathy. *Eur J Neurol* 2016; 23: 919-25.
223. Kim SH, Kwak K, Hyun JW, Jeong IH, Jo HJ, Joung A, Kim JH, Lee SH, Yun S, Joo J, Lee JM, Kim HJ. Widespread cortical thinning in patients with neuromyelitis optica spectrum disorder. *Eur J Neurol* 2016; 23: 1165-73.

Headache

224. Sarchielli P, Corbelli I, Messina P, Cupini LM, Bernardi G, Bono G, Di P, V, Petolicchio B, Livrea P, Prudenzi MP, Pini LA, Sandrini G, Allena M, Tedeschi G, Russo A, Caproni S, Beghi E, Calabresi P. Psychopathological comorbidities in medication-overuse headache: a multicentre clinical study. *Eur J Neurol* 2016; 23: 85-91.
225. Zebenholzer K, Frantal S, Pablik E, Lieba-Samal D, Salhofer-Polanyi S, Wober-Bingol C, Wober C. Reliability of assessing lifestyle and trigger factors in patients with migraine--findings from the PAMINA study. *Eur J Neurol* 2016; 23: 120-6.
226. Guo S, Esserlind AL, Andersson Z, Frederiksen AL, Olesen J, Vissing J, Ashina M. Prevalence of migraine in persons with the 3243A>G mutation in mitochondrial DNA. *Eur J Neurol* 2016; 23: 175-81.
227. Wang X, Zhou HB, Sun JM, Xing YH, Zhu YL, Zhao YS. The prevalence of migraine in university students: a systematic review and meta-analysis. *Eur J Neurol* 2016; 23: 464-75.
228. Tjensvoll AB, Lauvsnes MB, Hirohata S, Beyer MK, Greve OJ, Kvivik I, Kvaloy JT, Harboe E, Goransson LG, Omdal R. Migraine in patients with systemic lupus erythematosus is associated with reduced cerebral grey matter volume but not with measures of glial activation or anti-NR2 or anti-P antibodies. *Eur J Neurol* 2016; 23: 780-6.
229. Pavao M, I. Better cognition in migraine? *Eur J Neurol* 2016; 23: 1487-8.
230. Cruccu G, Garcia-Larrea L, Hansson P, Keindl M, Lefaucheur JP, Paulus W, Taylor R, Tronnier V, Truini A, Attal N. EAN guidelines on central neurostimulation therapy in chronic pain conditions. *Eur J Neurol* 2016; 23: 1489-99.
231. Wen K, Nguyen NT, Hofman A, Ikram MA, Franco OH. Migraine is associated with better cognition in the middle-aged and elderly: the Rotterdam Study. *Eur J Neurol* 2016; 23: 1510-6.

General

232. Oliver DJ, Borasio GD, Caraceni A, de VM, Grisold W, Lorenzi S, Veronese S, Voltz R. A consensus review on the development of palliative care for patients with chronic and progressive neurological disease. *Eur J Neurol* 2016; 23: 30-8.
233. De BP, Lofrese G, Scoppettuolo G, Spanu T, Cultrera R, Labonia M, Cavallo MA, Mangiola A, Anile C, Pompucci A. Intraventricular versus intravenous colistin for the treatment of extensively drug resistant *Acinetobacter baumannii* meningitis. *Eur J Neurol* 2016; 23: 68-75.
234. Hanken K, Manousi A, Klein J, Kastrup A, Eling P, Hildebrandt H. On the relation between self-reported cognitive fatigue and the posterior hypothalamic-brainstem network. *Eur J Neurol* 2016; 23: 101-9.

235. Cho H, Kim C, Kim HJ, Ye BS, Kim YJ, Jung NY, Son TO, Cho EB, Jang H, Lee J, Kang M, Shin HY, Jeon S, Lee JM, Kim ST, Choi YC, Na DL, Seo SW. Impact of smoking on neurodegeneration and cerebrovascular disease markers in cognitively normal men. *Eur J Neurol* 2016; 23: 110-9.
236. Schmutzhard E, Pfausler B. Primum non nocere. *Eur J Neurol* 2016; 23: 219-20.
237. Provitera V, Gibbons CH, Wendelschafer-Crabb G, Donadio V, Vitale DF, Stancanelli A, Caporaso G, Liguori R, Wang N, Santoro L, Kennedy WR, Nolano M. A multi-center, multinational age- and gender-adjusted normative dataset for immunofluorescent intraepidermal nerve fiber density at the distal leg. *Eur J Neurol* 2016; 23: 333-8.
238. Karapetkova M, Koenig MA, Jia X. Early prognostication markers in cardiac arrest patients treated with hypothermia. *Eur J Neurol* 2016; 23: 476-88.
239. Nigri A, Ferraro S, Bruzzone MG, Nava S, D'Incerti L, Bertolino N, Sattin D, Leonardi M, Lundstrom JN. Central olfactory processing in patients with disorders of consciousness. *Eur J Neurol* 2016; 23: 605-12.
240. Yousif N, Bhatt H, Bain PG, Nandi D, Seemungal BM. The effect of pedunculo-pontine nucleus deep brain stimulation on postural sway and vestibular perception. *Eur J Neurol* 2016; 23: 668-70.
241. Auer M, Hegen H, Zeileis A, Deisenhammer F. Quantitation of intrathecal immunoglobulin synthesis - a new empirical formula. *Eur J Neurol* 2016; 23: 713-21.
242. Parker T, Keddle S, Kidd D, Lane T, Maviki M, Hawkins PN, Lachmann HJ, Ginsberg L. Neurology of the cryopyrin-associated periodic fever syndrome. *Eur J Neurol* 2016; 23: 1145-51.
243. Berghuis B, de Haan GJ, van den Broek MP, Sander JW, Lindhout D, Koeleman BP. Epidemiology, pathophysiology and putative genetic basis of carbamazepine- and oxcarbazepine-induced hyponatremia. *Eur J Neurol* 2016; 23: 1393-9.
244. Roth C, Stitz H, Roth C, Ferbert A, Deinsberger W, Pahl R, Engel H, Kleffmann J. Craniocervical manual lymphatic drainage and its impact on intracranial pressure - a pilot study. *Eur J Neurol* 2016; 23: 1441-6.
245. Kerkhof M, Hagenbeek RE, van der Kallen BF, Lycklama ANG, Dirven L, Taphoorn MJ, Vos MJ. Interobserver variability in the radiological assessment of magnetic resonance imaging (MRI) including perfusion MRI in glioblastoma multiforme. *Eur J Neurol* 2016; 23: 1528-33.
246. Grisold W. Neurologists cannot ignore global health issues. An initiative from young neurologists. *Eur J Neurol* 2016; 23: 1597-8.
247. Sauerbier A, Macerollo A, Gyorfı O, Balicza P, Moarcas M, Papp V, Zis P, Klingelhofer L, Saifee T, Struhal W, Sellner J. Insufficient global health education in European neurological post-graduate training: a European Association of Young Neurologists and Trainees survey. *Eur J Neurol* 2016; 23: 1680-3.
248. Schapira AH. Advances in neurological research and practice. *Eur J Neurol* 2016; 23: 1685-93.